The main signs of COVID-19 are respiratory symptoms, like congestion and a cough. But COVID-19 can also cause skin rashes, ...
A young British woman suffers from an extremely rare allergy to water, which keeps her away from taking a shower or cleaning ...
At the same time, her rash returned, resulting in a UAS score ... even in the absence of any active anti-urticaria treatment. She received adjuvant left whole breast radiation therapy 26 Gy ...
Yeast infection” is the term used to describe chronic and persistent fungal infections of the skin, mouth, digestive system ...
Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
Smith, 55, is further impacted by mastocytosis, a rare condition where the body makes too many mast cells. Mast cells are a ...
An EPA investigation confirmed residents’ worst fears about operations at an industrial landfill. What happens next is all too uncertain.
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).
US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback